After the publication of the Review by Bastiaan E de Galan, Can inhaled insulin be used for the treatment of diabetes mellitus?, published in the January 2008 issue of Expert Review of Pharmacoeconomics & Outcomes Research (Expert Rev. Pharmaco-economics Outcomes Res. 8[1], 33–42 [2008]), it has been brought to our attention that the following was written incorrectly:
Technosphere® insulin is a dry-powder pulmonary insulin packaged in microparticles to which an absorption enhancer is added.
The correct text is given below:
Technosphere® insulin (TI) is a dry-powder pulmonary insulin formation in which insulin is absorbed onto the surface of Technosphere® microparticles. TI does not contain any absorption enhancers. TI powder is appropriately sized for inhalation into the deep lung where the particles rapidly dissolve and insulin is absorbed by natural mechanisms.
The editors of Expert Review of Pharmacoeconomics & Outcomes Research and authors would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.